Browse diseases

…se I trial data demonstrates clinical activity in patients with solid tumors, with a number of durable responses. This data supports the pot…

…B response in eight new and diverse clinical cohorts; including melanoma, NSCLC, breast, renal, bladder, and HNSCC; with a mean AUC of 0…

…oss over 40 million cells from 1399 non-small cell lung cancer (NSCLC) tumor resections. 1 2 This model allows the simulation of gene…

…1 therapy.Methods DBA/2 mice bearing subcutaneous KLN205 murine NSCLC tumors were treated with anti-PD-1 antibodies in combination wi…

…hat have characteristically high oligomannose residues, such as non-small cell lung cancer (NSCLC).Methods Design, purification and characterization of le…

…ize tumor-infiltrating lymphocytes (TILs). Tumor types included NSCLC (HER2, Trop2, FRα, cMET), HER2+ breast carcinoma (HER2, Trop2, …

…ll lung cancer (NSCLC, n=30), colorectal cancer (CRC, n=33) and urothelial cancer (UC, n=30) resection samples. We present a comparative analysis…

…d to both published 1-3 and two new cohorts (n=45 and n=136) of non-small cell lung cancer (NSCLC) patients, to uncover consistent predictors of ICI respo…

…only used in patients with advanced non-small cell lung cancer (NSCLC), the benefit is variable. We have previously reported results …

…Background Oncogenic mutations are prevalent in non-small cell lung cancer (NSCLC) and associated with lack of response to checkpoint bloc…

…ts. However, their use remains largely confined to melanoma and NSCLC due to systemic Treg depletion and related peripheral toxicity.…

…+N therapy.Methods Immunotherapy-naïve patients with metastatic NSCLC were treated with ipilimumab and nivolumab per the LONESTAR tri…